A5024889229- Alzheimer's disease research and treatments
- Immunotherapy and Immune Responses
- MicroRNA in disease regulation
- T-cell and B-cell Immunology
- Neuroinflammation and Neurodegeneration Mechanisms
- Pluripotent Stem Cells Research
- Extracellular vesicles in disease
- Computational Drug Discovery Methods
- vaccines and immunoinformatics approaches
- Immune Response and Inflammation
- Circular RNAs in diseases
- Nanoplatforms for cancer theranostics
- SARS-CoV-2 and COVID-19 Research
- Tryptophan and brain disorders
- Renal and related cancers
- Protein Structure and Dynamics
- Prion Diseases and Protein Misfolding
Institute of Genetics and Biophysics
2010-2022
National Research Council
2012-2022
The immune system is able to respond more vigorously the second contact with a given antigen than first contact. Vaccination protocols generally include at least two doses, in order obtain high antibody titers. We want analyze relation between time elapsed from dose (priming) and (boost) on In this paper, we couple vivo experiments computer simulations assess effect of delaying injection. observe that an interval several weeks prime boost necessary optimal responses.
Tumor growth and metastasis strongly rely on cell-cell communication. One of the mechanisms by which tumor cells communicate involves release uptake lipid membrane encapsulated particles full bioactive molecules, called extracellular vesicles (EVs). EV exchange between cancer may induce phenotype changes in recipient cells. Our work investigated effect EVs released teratocarcinoma glioblastoma (GBM) were isolated differential centrifugation analyzed through Western blot, nanoparticle...
The development of active immunotherapy for Alzheimer's disease (AD) requires the identification immunogens that can ensure a high titer antibody response toward Aβ, while minimizing risks adverse reactions. Multimeric protein (1–11)E2 induces robust and persistent to Aβ in mice, when formulated Freund's adjuvant. goal this translational study was evaluate immunogenicity alum (Alhydrogel 2%), or squalene oil-in-water emulsion (AddaVax), without A IgG1-skewed isotype distribution observed...
The development of active immunotherapy for Alzheimer's disease (AD) requires the identification immunogens that can ensure a high titer antibody response toward beta‐amyloid, whereas minimizing risks cell‐mediated adverse reaction. We describe here two novel anti‐beta‐amyloid vaccines consist ‘virus like particles’ formed by domain bacterial protein E2 is able to self‐assemble into 60‐mer peptide. Peptides 1–11 and 2–6 beta‐amyloid were displayed as N terminal fusions on surface particles....
Proper regulation of neurogenesis, the process by which new neurons are generated from neural stem and progenitor cells (NS/PCs), is essential for embryonic brain development adult function. The transcription regulator Patz1 ubiquitously expressed in early mouse embryos has a key role cell maintenance. At later stages, detection expression mainly developing suggests specific involvement neurogenesis. To address this point, we first got insights profile different territories at both postnatal...
Long lasting antibody responses and immunological memory are the desired outcomes of vaccination. In general, multiple vaccine doses result in enhanced immune responses, a notable exception being booster-induced hyporesponsiveness, which has been observed with polysaccharide glycoconjugate vaccines. this study, we analyzed effect early booster multimeric protein (1-11)E2 on recall to B epitope 1-11 β-amyloid. Mice immunized single dose stochastically display, when 9 months later, either...
Abstract Immunization against β-amyloid (Aβ) is pursued as a possible strategy for the prevention of Alzheimer’s disease (AD). In clinical trials, Aβ 1–42 proved poorly immunogenic and caused severe adverse effects; therefore, safer more candidate vaccines are needed. Multimeric protein (1–11)E2 able to induce an antibody response Aβ, immunological memory, IL-4 production, with no concomitant anti-Aβ T cell response. Antisera recognize oligomers, protofibrils, fibrils. this study, we...
Immunological memory can be defined as the ability to mount a response of greater magnitude and with faster kinetics upon re-encounter same antigen. We have previously reported that booster dose protein antigen given 15 days after first interferes development memory, i.e., an epitope-specific IgG named time-window during which is vulnerable disruption "consolidation phase in immunological memory", by analogy consolidation processes occur nervous system stabilize traces. In this study, we set...